Project Title: Targeting ER stress-induced neurotropism as a therapy in glioblastoma
Chief Investigators: Professor Hubert Hondermarck and Dr Chen Chen Jiang (The University of Newcastle)
Imagine if we could eliminate resistance to treatments in GBM
Current treatments for glioblastoma (GBM) are all aimed at targeting cancer cells, but unfortunately, they are not effective for most patients. Professor Hubert Hondermarck and his team have obtained evidence showing that nerve cells stimulate the growth of GBM and contribute to the problem of current therapies not working.
GBM cells grow fast, their molecular machinery undergoes heavy stress, resulting in the release of growth factors that attract neurons into the tumour, which fuel tumour progression and resistance to chemo- and radiotherapies. Professor Hondermarck aims to target the nerve cells-cancer cell crosstalk mediated by cellular stress, to ultimately eliminate resistance to treatments in GBM.
The nerve-cancer crosstalk is an emerging driver of tumour initiation and progression. The team thinks this explains why brain tumours (particularly GBMs), are so aggressive: they develop in a nerve cell microenvironment where the stimulatory impact of nerve cells is maximal. Work is underway to target important proteins in pathway, to disrupt the nerve-cancer cell crosstalk, inhibit the stimulatory impact of nerve cells and therefore help treatments to work better on GBM. Once the team can show this happens in the lab using the funding generously provided by MHF, the next step will be to test this in patients in a clinical trial.
Acknowledgement of donor:
Through your kind donation, the team is testing test a new and innovative therapeutic option to treat GBM by targeting the crosstalk between neurons and GBM cells. If the team can achieve this, it would conceptually and practically change our knowledge of and clinical management of GBMs.